CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, 12 January at 0815hrs PT in San Francisco.
A live webcast of the presentation will be available on the ‘Events & Presentations’ page in the Investors section of the Company’s website. A replay of the webcast will be archived on the Company’s website for 14 days following the presentation.
Founded over a decade ago, CRISPR Therapeutics is a leading gene editing company focused on developing transformative medicines for serious diseases. The Company has evolved from a pioneering research-stage organisation into an industry leader, marking a historic milestone with the approval of CASGEVY® (exagamglogene autotemcel [exa-cel]), the world’s first CRISPR-based therapy, approved for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia.
